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he Spring 2018 edition of Neurotransmitter demonstrates that the rigorous fields of 
the basic and clinical neurosciences have spiritual and artful sides. 
Since its inception, Neurotransmitter has been decorated with art that plays off 
the subjects of its articles. This edition produces its own art. Within these pages, you 
can see a beautiful microscopic image of nerve bodies and their supporting cells 
taken by first-year MD student Aslam Akhtar, PhD, as part of his research studies of 
the olfactory bulb, an area of the brain critical to the sense of smell. His photo could 
hang in any Washington, D.C., gallery, but it also educates about the complexity of 
the brain. 
James L. Griffith, MD, chair of the Department of Psychiatry and Behavioral 
Sciences and Leon M. Yochelson Professor of Psychiatry and Behavioral Sciences, 
was honored for his lifetime of work leveraging the power of religious belief in 
psychiatric therapy, especially for those of us suffering profound traumas. 
You also can read about virtual reality technology that allows our neurosurgeons 
to map complex surgeries to remove tumors or treat blood vessel abnormalities 
before they enter the operating room. Here again, the images demonstrate the 
beauty and complexity that is the human brain. 
Director of the George Washintgon University (GW) Institute for Neuroscience 
Anthony-Samuel LaMantia, PhD, professor of pharmacology and physiology, 
was honored recently in two ways. First, the sixth edition of LaMantia’s textbook, 
Neuroscience, was published. The book has become the standard for the field and 
is the source for budding neuroscientists to receive their education. Second, GW’s 
School of Medicine and Health Sciences (SMHS) acknowledged his excellence by 
naming him the Jeffrey Lieberman Professor of Neurosciences. Joining LaMantia 
as an endowed professor is GW resident alumnus Brandon Kohrt, MD, PhD, RESD 
’13, associate professor of psychiatry and behavioral sciences, who became the 
Charles and Sonia Akman Professor in Global Psychiatry. Not only is an endowed 
professorship a prestigious appointment at any academic institution, but it also 
provides financial support of neuroscience research at GW and honors the donor 
in perpetuity. Such endowments are the lifeblood of universities from the time they 
were first established at Oxford University centuries ago. 
Neurotransmitter further spans the breadth of the neurosciences with stem 
cell treatments for multiple sclerosis and brain stem physiology that could lead 
to potential therapies for sleep apnea. As you will appreciate, discoveries occur 
through the collaboration of many scientists and physicians. This is the strength of 
GW Hospital, GW Medical Faculty Associates, and SMHS. 
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CONTEST HIGHLIGHTS THE ART  
OF SCIENTIFIC RESEARCH AT SMHS
Looking at a winning submission for the first-ever 
George Washington University (GW) School of 
Medicine and Health Sciences (SMHS) Art of Sci-
ence Contest, one might not know the bright pur-
ple and green colors represent olfactory bulb inter-
neurons and astrocytes in the brain, but that’s the 
beauty of art: there’s more to it than meets the eye. 
The contest shows off the amazing research 
medical students, graduate students, and post-
doctoral fellows are conducting “through dynamic 
and beautiful images,” said Alison Hall, PhD, associ-
ate dean for research workforce development and 
professor of neurology at SMHS.  
The four contest winners — chosen by a team of 
SMHS deans, students, and staff — will have their images displayed in the SMHS Dean’s 
Suite in Ross Hall.
Grand prize winner and first-year MD student Aslam Akhtar, PhD, said a push from 
classmates and class discussions about the olfactory bulb neurons — the neurons re-
sponsible for our sense of smell — led him to enter his image in the contest.
“I hope when someone walks by they reflect more about the deeper meaning,” 
Akhtar said, adding hopefully “it will create an appreciation for the complexity of the 
brain and the lifelong impacts that diseases of the brain can have.”
The image, he added, arose from his neurodevelopmental research into how neu-
rons in the brain develop from neural stem cells after birth. “There are only a few re-
gions of the brain where neurons are generated after birth, the olfactory bulb being 
one of these regions,” he said. “If we can better understand the characteristics of the 
stem cells that generate these neurons, we can apply that knowledge toward replacing 
or supporting cells lost in neurodegenerative diseases.”
This year, 12 images were submitted for consideration, and Hall said she hopes even 
more images, reflecting even broader approaches to research, are submitted in the 
years to come. The contest will be an annual event.
Winner Shabnum Patel, PhD, a post-doctoral fellow with the GW Cancer Center, 
submitted an image showing her immunotherapy research. “For this image, we were 
focused on making Mucor-specific T-cells to fight the fungal infection Mucormycosis,” 
she said. “We thought [the contest] would be a nice way not only to display a beautiful 
picture, but also to get people interested in the type of research that we do.”
Hall added that the beauty of the entries is what makes the contest so interesting.
“[When choosing a winner,] we didn’t ask ‘Is this an important scientific advance-
ment?’ or ‘Is this technique important?’ We were really just looking at how attractive 
it was,” Hall said. “But beneath these pretty images are major advances in our under-
standing of biomedical science and potential medical advances.”
“[When choosing 
a winner,] we didn’t 
ask ‘Is this an 
important scientific 
advancement?’ or 
‘Is this technique 
important?’ We were 
really just looking 
at how attractive it 
was. But beneath 
these pretty images 
are major advances 
in our understanding 
of biomedical 
science and potential 
medical advances.”
Alison Hall, PhD
“I hope when someone walks by they reflect more about the deeper meaning. 
[Hopefully] it will create an appreciation for the complexity of the brain 
and the lifelong impacts that diseases of the brain can have.” 
Aslam Akhtar, PhD, first-year MD student
THE BEAUTY OF SCIENCE
First-year MD student Aslam 
Akhtar, PhD, is the inaugural 
grand prize winner of the 
George Washington Univer-
sity School of Medicine and 
Health Sciences Art of Science 
Contest. Akhtar’s image was 
selected from the 12 images 
submitted for consideration.
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WHERE RELIGION 
MEETS PSYCHIATRY
James L. Griffith, MD, received 
the American Psychiatric Associa-
tion’s Oskar Pfister Award. The 
award, which is named after a 
Lutheran minister, is presented 
to individuals who have made 
outstanding contributions to the 
understanding of the interplay 
between religion and psychiatry. 
DRAWING STRENGTH FROM THE SPIRITUAL SIDE
James L. Griffith, MD, chair for the Department of Psychiatry and Behavioral Sciences 
and Leon M. Yochelson Professor of Psychiatry and Behavioral Sciences at the George 
Washington University School of Medicine and Health Sciences, received the Oskar 
Pfister Award from the American Psychiatric Association during the association’s Insti-
tute on Psychiatric Services: The Mental Health Services Conference in New Orleans.
The award — named in honor of Oskar Pfister, a Lutheran minister who studied and 
used psychoanalytic principles in his work — is presented annually to individuals who 
have made outstanding contributions to the understanding of the interplay between 
religion and psychiatry. 
Over the course of his career, Griffith has focused on helping clinicians learn how 
to draw from patients’ spiritual resources when helping them to cope and sustain resil-
ience in the face of disease, disability, and suffering. He has become a global mental 
health leader, providing psychiatric treatment for immigrants, refugees, and survivors 
of political torture.
At the meeting, Griffith also delivered the Oskar Pfister Award Lecture, “Hope Mod-
ules: Brief Psychotherapeutic Interventions to Counter Despair from Chronic Adversi-
ties.” Griffith described his work developing brief interventions to help patients sustain 
hope despite demoralizing life circumstances and methods for teaching trainees and 
other clinicians.
Academic publisher Sinauer Associates announced this fall the release of the sixth 
edition of Neuroscience, co-authored and co-edited by Anthony-Samuel LaMantia, 
PhD, director of the George Washington University (GW) Institute for Neuroscience 
(GWIN), Jeffrey Lieberman Professor of Neurosciences, and professor of pharmacology 
and physiology at GW’s School of Medicine and Health Sciences (SMHS). Since its initial 
publication, the comprehensive text has grown to become a standard in the dynamic 
field of neuroscience, spanning topics from cellular signaling to cognitive function.
The best-selling and most widely used text for medical and undergraduate neuro-
science courses has been a combined effort over its many years, according to LaMan-
tia, and features co-authors and editors from Duke Institute for Brain Sciences; Duke 
University School of Medicine; Lee Kong Chian School of 
Medicine, Nanyang Technological University, Singapore; 
the Max Planck Florida Institute for Neuroscience; and the 
University of Pennsylvania. 
This recent edition is also the first published since Sinau-
er became a subsidiary of Oxford University Press. “That 
means that the book … has a larger audience as part of the 
Oxford University Press orbit,” said LaMantia. 
“I think everyone is very enthusiastic,” he added. “It’s an 
interesting time for this aspect of academic science, educa-
tion, neurosciences, and academic publishing.”
New to this edition is an expanded cognitive 
neuroscience unit, with chapters on attention, decision-
making, and evolution of cognitive functions; an updated 
neural signaling unit; and new clinical applications boxes 
and web essays.
“It’s an interesting 
time for this 
aspect of academic 
science, education, 
neurosciences, 
and academic 
publishing.” 
Anthony-Samuel 
LaMantia, PhD
A NEW RELEASE 
The sixth edition of Neurosci-
ence, co-authored and co-edited 
by Anthony-Samuel LaMantia, 
PhD, was released by Sinauer 
Associates, a subsidiary of 
Oxford University Press, in the 
fall of 2017. Since its initial 
publication, the textbook has 
become the most widely used 
text for medical and under-
graduate neuroscience courses. 
It is now a standard in the 
dynamic field of neuroscience.
SETTING THE STANDARD FOR NEUROSCIENCE,  
RESEARCHERS RELEASE SIXTH EDITION OF ACCLAIMED TEXT
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he George Washington 
University (GW) had an 
enhanced presence at 
one of the largest neu-
roscience conferences 
in the world, The Society 
for Neuroscience 2017 
Annual Meeting, held at the Walter E. 
Washington Convention Center in mid-
November. 
The meeting drew more than 
30,000 scientists from throughout the 
world to Washington, D.C., for a week 
of presentations and intellectual ex-
changes about the brain, how it works, 
how it develops, and the challenges of 
solving brain diseases. 
Anthony-Samuel LaMantia, PhD, 
director of the GW Institute for Neu-
roscience, Jeffrey Lieberman Profes-
sor of Neurosciences, and professor 
of pharmacology and physiology at 
GW’s School of Medicine and Health 
Sciences (SMHS), said the meeting 
comes to Washington, D.C., every three 
years, and this year GW’s presence was 
expanded to include satellite sessions 
held on the GW Foggy Bottom campus. 
LaMantia added that both the 
promise and challenge of having such 
a prominent role at the meeting is to 
continue to expand GW’s neurosci-
ence community to be a part of all the 
changes happening in the field. The 
last several years have brought ro-
bust growth to neuroscience research 
at GW, and there is a commitment to 
continue to grow in this critical area of 
biomedical research.
Throughout the meeting, GW neu-
roscientists from SMHS, the Columbi-
an College of Arts and Sciences, and 
the Milken Institute School of Public 
GW Expands Presence  
at Neuroscience 2017
T
Health at GW presented nearly 60 re-
search posters.
SMHS faculty also spoke at the 
event, including Robert H. Miller, PhD, 
senior associate dean of research, Viv-
ian Gill Distinguished Research Pro-
fessor, and professor of anatomy and 
regenerative biology; Vittorio Gallo, 
PhD, associate dean for child health re-
search and professor of pediatrics; and 
Kevin Pelphrey, PhD, director of the 
GW Autism and Neurodevelopmental 
Disorders Institute and Carbonell Fam-
ily Professor in Autism and Neurode-
velopmental Disorders. 
One of the main takeaways from 
the event, LaMantia said, is the growth 
in addressing translational issues of 
neuroscience. “I think we want to de-
velop more aspects of translational 
research at GW, because that is some-
thing more and more being featured 
in the field,” he said. Recent progress, 
attendees reported, hold promise for 
new approaches to disorders that pre-
viously were thought insoluble. These 
include neurodegenerative disorders 
like Alzheimer’s and neurodevelop-
mental disorders like autism spectrum 
disorder.  
“I think it will be interesting in 2020, 
when Neuroscience returns to D.C., to 
see [what direction research has taken 
the profession],” LaMantia added. “The 
field has grown, but it’s also changed. I 
am hopeful that will continue, and that 
we will even have a bigger presence in 
2020.”
Neuroscience 2017 drew more than 30,000 scientists 
from throughout the world to Washington, D.C. 
THE MEETING OF PEERS
The Society for Neuroscience 2017 
Annual Meeting was held at the 
Walter E. Washington Conven-
tion Center in mid-November. 
The conference, one of the 
largest neuroscience confer-
ences in the world, will return 
to Washington, D.C., in 2020.
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Brandon Kohrt Installed as 
Charles and Sonia Akman 
Professor in Global Psychiatry
angeeta, Ramesh, Asha. 
Those are names of chil-
dren whose lives were 
restored thanks to the 
efforts of global mental 
health expert Brandon 
Kohrt, MD, PhD, RESD ’13, associate 
professor of psychiatry and behavioral 
sciences at the George Washington 
University (GW) School of Medicine 
and Health Sciences (SMHS). Kohrt 
shared their stories at his installment 
as the Charles and Sonia Akman Pro-
fessor in Global Psychiatry.
“We are all part of the George 
Washington University because of the 
dedication to improving the quality of 
the human experience and to reduc-
ing human suffering through research, 
education, and service,” Kohrt said. “I 
am deeply grateful … for the opportu-
nity to pursue this mission to its fullest 
extent.”
The endowed fund was made in 
memory of the parents of Leonard 
C. Akman, MD ’43, a pioneer in heart 
transplantation and cardiac catheter-
ization and cousin to Jeffrey S. Ak-
man, MD ’81, RESD ’85, vice president 
for health affairs, Walter A. Bloedorn 
Professor of Administrative Medicine, 
and dean of SMHS. When Leonard Ak-
man passed away, he left SMHS a $3.2 
million gift to support a variety of initia-
tives, the choosing of which he left to 
his cousin. 
Kohrt has worked on mental health 
in Nepal since 1996 and as an adviser 
to the Transcultural Psychosocial Or-
ganization in Nepal since 2006. He 
also has collaborated with The Carter 
Center Mental Health Program in Libe-
ria since 2010, and he has investigated 
the mental health consequences of 
and designed interventions for child 
soldiers and earthquake survivors in 
Nepal. 
In addition, Kohrt collaborated on 
the development of a Nepali school-
based youth suicide prevention pro-
gram. And, in Liberia, Kohrt designed 
programs to reduce stigma among 
youth and adults affected by mental ill-
ness, political violence, and the Ebola 
outbreak. “He has worked in South 
Africa, Ethiopia, Mongolia, Haiti, and 
India,” said Forrest Maltzman, provost 
and executive vice president for aca-
demic affairs at GW. “He is changing 
the world, and he is never sleeping.”
CHANGING THE 
LIVES OF CHILDREN 
Brandon Kohrt, MD, PhD, 
RESD ’13, (right) was recently 
installed as the Charles and So-
nia Akman Professor in Global 
Psychiatry. In his career, Kohrt 
has worked to reduce stigma 
among youth and adults affect-
ed by mental illness, political 
violence, and physical illness 
in countries such as Nepal, 
Liberia, South Africa, Ethiopia, 
Mongolia, Haiti, and India.
“We are all part of the George Washington University because of the 
dedication to improving the quality of the human experience and to 
reducing human suffering through research, education, and service.”
Brandon Kohrt, MD, PhD, RESD ’13
S
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Saving Sleep, 
Counting Sheep
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e’ve all been there at some 
point, tossing and turning 
and counting down the 
minutes before the alarm 
goes off and the day be-
gins. For more than a third 
of the American popula-
tion, however, sleep disorders such as insomnia, 
sleep apnea, narcolepsy, and restless legs syn-
drome make those struggles a nightly occurrence, 
often putting those precious seven to eight hours of 
sleep out of reach. 
Insufficient sleep is more than an inconvenience; 
it can cause serious long-term cardiac and neuro-
logical problems, including increased risk of hy-
pertension, stroke, and even cognitive impairment, 
GEORGE WASHINGTON MEDICAL FACULTY 
ASSOCIATES CENTER FOR SLEEP DISORDERS 
FOCUSES ON HELPING PATIENTS CATCH SOME Zs
BY KATHERINE DVORAK
according to David Mendelowitz, PhD, vice chair 
and professor of pharmacology and physiology at 
the George Washington University (GW) School of 
Medicine and Health Sciences (SMHS). 
Mendelowitz says there’s growing recognition 
of the intersection between conditions such as ob-
structive sleep apnea and serious neurologic disor-
ders. “More work is beginning to touch on the hy-
pothesis that sleep apnea might be involved in more 
long-term problems, such as Alzheimer’s disease,” 
he says.
One of Mendelowitz’s efforts is finding novel 
treatments for obstructive sleep apnea, a chronic 
condition involving an intermittent blockage of the 
upper airway during sleep, which is associated with 
snoring, pauses in breathing, and excessive sleepi-
ness. More than 18 million adults in the United States 
suffer from the disorder, according to the National 
Sleep Foundation.
“There are very significant cardiovascular conse-
quences of sleep apnea. We’re interested in what 
changes in the central nervous system, particularly 
in the brain stem, occur during sleep apnea to ini-
tiate and/or sustain these cardiovascular diseases,” 
Mendelowitz says. “At the same time, we want to 
identify targets of opportunity for treating sleep ap-
nea to reduce the dysfunction of the cardiovascular 
system and reduce the risks of adverse cardiovascu-
lar events.”
However, sleep apnea is often underdiagnosed. 
The closure of the airway, says Vivek Jain, MD, medi-
cal director of the GW Medical Faculty Associates’ 
(MFA) Center for Sleep Disorders and associate pro-
fessor of medicine at SMHS, often goes unnoticed 
during sleep. “Most patients won’t recognize they 
have sleep apnea,” Jain says. “For every patient [with 
sleep apnea] we see in the clinic, or in general in the 
country, I think there are probably two out there who 
haven’t been tested.”
Jain adds that the symptoms of sleep apnea — 
fatigue, daytime sleepiness, or interrupted sleep 
— usually are what drive patients to the Center for 
Sleep Disorders.
Patients diagnosed with sleep apnea are often 
prescribed a continuous positive airway pressure 
“More work is beginning to touch on the hypothesis 
that sleep apnea might be involved in more long-
term problems, such as Alzheimer’s disease.” 
David Mendelowitz, PhD
W
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therapy (CPAP) device. The machine, which includes 
a plastic mask that fits over a user’s nose and some-
times mouth, is worn during sleep and helps to in-
crease air pressure so the airway doesn’t collapse 
when a person inhales. CPAP machines are 100 per-
cent effective when patients use them, notes Jain. 
Unfortunately, he adds, they have low compliance. 
“At least 50 percent of the patients who are pre-
scribed CPAP machines discontinue their use or use 
them for less than four hours a day,” Mendelowitz 
says. “It’s extremely uncomfortable, awkward, and 
it’s not the sexiest thing in the world to be sleeping 
with a mask on your face.”
Currently there are no pharmacological treat-
ments for the disorder, he notes. But, Jain and Men-
delowitz are collaborating on translational research 
in the hope of discovering such an option.  
“Two graduate students in my lab … were look-
ing at a pathway from the hypothalamus to neurons 
that are important in autonomic control. They found 
that there’s a specific population of neurons in the 
paraventricular nucleus of the hypothalamus that 
releases oxytocin, which in turn excites autonomic 
parasympathetic neurons to the heart and restores 
autonomic balance,” Mendelowitz explains. “We 
found in our work that activation of these oxytocin 
neurons prevented the hypertension that occurs in 
an animal model with sleep apnea.”
After the discovery, Mendelowitz approached 
Jain about conducting a pilot project to test if oxyto-
cin would be beneficial in patients with sleep apnea. 
Eight patients diagnosed with sleep apnea present-
ed for a sleep study and received a dose of oxytocin 
via a nasal spray before bed. 
Their initial findings were positive, Jain and Men-
delowitz say, showing that oxytocin may play a role 
in shortening apnea duration and lessening night-
time arousals. “These patients did subjectively feel 
better. [It’s an] uncontrolled, non-blinded, non-ran-
domized placebo control study, but it’s a good be-
ginning,” Jain says.
While sleep apnea is one of the main disorders 
for which patients seek out the sleep center, it’s not 
the most common, Jain says. Although people may 
not see it as a disorder, sleep deprivation is one of 
the most prevalent sleep conditions, he notes, and 
insomnia, the inability to fall asleep or return to 
sleep in the night, comes in second. 
In addition, says Mendelowitz, a lot of these con-
ditions can be overlapping; someone can have both 
sleep deprivation and sleep apnea.
Another sleep disorder, which affects 10 percent 
of U.S. adults, is restless legs syndrome. Elias Kar-
roum, MD, PhD, assistant professor of neurology at 
SMHS and a neurologist at the MFA, whose research 
focuses on the condition, notes that restless legs 
syndrome differs from other sleep disorders be-
SIGNS OF SLEEP APNEA
 > Snoring that’s interrupted with periods of quiet 
 > Snoring that resumes with a loud sound as 
breathing restarts 
 > Morning headaches
 > Frequently falling asleep during the day
 > Being easily irritated
 > Depression
 > Difficulty remembering things
For more than a third of the American population, 
sleep disorders such as insomnia, sleep apnea, 
narcolepsy, and restless legs syndrome make 
getting enough sleep a nightly struggle. 
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WHAT TO EXPECT AT THE SLEEP CLINIC
When arriving at the MFA Center for Sleep Disorders, 
patients give detailed histories of their sleep patterns. 
Some of the questions asked include: What time do you 
go to bed? How many minutes does it take you to fall 
asleep? Do you fall asleep at inappropriate times? Do 
you snore? 
If overnight monitoring is deemed necessary to di-
agnose the right sleep disorder, a patient will either be 
brought to the lab — located at 2021 K St., NW — for a 
sleep study, or given monitors to take home. 
At home: Home monitors are not as extensive as 
those used in clinic-based sleep studies. These devices 
simply record breathing and oxygenation. If the home 
monitor shows a mild case of a disorder such as sleep 
apnea, then an in-lab study may be requested to con-
firm the findings. 
In the lab: Patients spend the night in a hotel-like 
setting to have their sleep monitored. Study arrival time 
is 8:30 p.m., at which point a patient is prepped for a 
polysomnography test, which takes about 45 minutes. 
The test looks at brain-wave patterns and physiologic 
function during sleep. Sensors are placed on the face 
and scalp to measure electrical activity in the brain, a 
sensor by the nose records respiration rates, and oxy-
genation is measured using a finger probe, and belts 
on the chest and abdomen measure breathing effort.
While it’s expected that patients won’t have a per-
fect night’s sleep in the lab — people rarely do when not 
in the comfort of their own beds — disorders like sleep 
apnea will surface even if subjects only get a few hours 
of shut eye.  
“Even if you sleep on the Metro, or fall asleep at 
home on the couch, you will have sleep apnea,” says 
Jain. “It’s a sleep phenomenon; it’s not a stress-related 
phenomenon or environment-related phenomenon.”
cause it happens while a person is awake. 
Also known as Willis-Ekbom Disease, the disor-
der causes uncomfortable sensations in the legs 
and an irresistible urge to move them. It happens to 
people in the evening or at night while they are still 
awake and can prevent people from falling asleep, 
which can lead to insomnia, says Karroum. 
“I like to think of it as a resting wakefulness disorder 
with a core sensory component of feeling the need to 
move the limbs,” he explains. In addition, in up to half 
of the patients, the abnormal sensations are not only 
unpleasant, but also quite painful. Karroum says one 
reason he is studying this disorder is because there is 
still a lot to learn about it, including what causes the 
sensations and pain in these patients. 
Two to 3 percent of U.S. adults experience mod-
erate to severe cases of restless legs syndrome, 
in which the sensation occurs two to three times a 
week and negatively affects a patient’s daily life, 
Karroum says. For those patients, he’ll recommend 
a small dose of dopamine agonists, which mimic the 
neurotransmitter dopamine in the brain. 
Jain says while research on sleep has picked up 
in the last 20 years, “there’s still more to be done.”
“People may blow a lack of sleep off, saying ‘oh, I 
get six hours of sleep at night,’ and they don’t even 
bat an eye. But six hours of sleep is not right. It really 
has its own independent negative effects on health, 
including many cardiovascular diseases, obesity, 
and diminished cognitive awareness,” he says. “Peo-
ple talk about impairment of alcohol, but we should 
also open the conversation on impairment due to 
sleep problems.”
“People talk about impairment of alcohol, 
but we should also open the conversation 
on impairment due to sleep problems.” 
Vivek Jain, MD
Insufficient sleep can cause serious long-term cardiac 
and neurological problems, including increased risk of 
hypertension, stroke, and even cognitive impairment.
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ell therapy is number one on the research rock charts. The practice of 
transferring intact, live cells into a patient to help lessen or cure a dis-
ease is rapidly expanding, and in the United States alone, there current-
ly are more than 15,000 active clinical trials in the field.
One of the most promising therapies is the transplantation of mes-
enchymal stem cells (MSCs), which are multipotent cells present in mul-
tiple tissues including umbilical cord, bone marrow, and fat. MSCs give 
rise to bone, cartilage, muscle, and adipocytes (fat cells), which promote marrow adi-
pose tissue. These versatile cells are particularly suited as a cellular therapy for autoim-
mune diseases, including multiple sclerosis (MS), and they have immunosuppressive 
and tissue repair properties that lend themselves to therapy for inflammatory diseases. 
Based on their success in treating animal models of MS-like experimental autoimmune 
encephalomyelitis (EAE) — a brain-inflammatory disease of the central nervous system 
that erodes the myelin sheath protecting nerves — MSCs have moved rapidly into clini-
cal trials for MS. 
Such a trial is described in a research paper co-authored by Robert H. Miller, PhD, 
senior associate dean for research, Vivian Gill Distinguished Research Professor, and 
professor of anatomy and regenerative biology at the George Washington University 
School of Medicine and Health Sciences. Despite the hope and promise resting on 
MSCs, the clinical trial failed to show significant improvement, resulting in the conclu-
sion that central nervous system damage diminishes the therapeutic function of bone 
marrow MSCs.
Of Mice and MSCs
C
MESENCHYMAL STEM CELL RESEARCH OFFERS PROMISE AND PUZZLES 
BY STEVE GOLDSTEIN
Robert H. Miller, PhD, senior associate dean 
for research, Vivian Gill Distinguished 
Research Professor, and professor of 
anatomy and regenerative biology
GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES    11
“This is a pretty interesting cell therapy — it’s one of the 
most interesting of the therapies around,” Miller says. “There 
are something like 27 MSC clinical trials going on now.”
In the paper, Miller reports that bone marrow MSCs de-
rived from mice with encephalomyelitis weren’t as effec-
tive at treating the disease as those from uninfected mice. 
Similarly, the cells derived from MS patients showed less 
therapeutic efficacy in treating EAE, and researchers also 
observed the secretion of higher levels of some pro-in-
flammatory proteins. The results, showing diseases such 
as EAE and MS reduce the therapeutic effectiveness of bone marrow MSCs, are leading 
researchers to rethink the use of a patient’s own MSCs as a potential MS treatment.
Despite the outcome, Miller is upbeat about the therapeutic value of MSCs, recalling 
how, before this study, they found human mesenchymal stem cells were very effective 
in reducing the disease burden in animals. “When we got that data, I went to see Jeff 
Cohen at the Cleveland Clinic … and he put the clinical trial together with 12 patients — 
all of whom had MS,” says Miller.
As Miller explains in the paper, MSCs are defined experimentally as a population 
of cells that “stick to things” and can generate the major connective tissue derivatives, 
such as fat and mesenchymal tissues. They also are self-renewing, so they can divide. 
“We know they live in bone marrow, and we know they live in fat and adipose tissues, 
and some people think they are parasites that live around vasculature in many organs,” 
Miller explains. “They are relatively hard to isolate.” 
Putting human MSCs into mice, according to Miller, was effective at reducing dis-
ease, and putting mouse cells into mice is also effective at reducing disease. In human 
trials, however, the treatment has not proven to be as effective in reducing disease. 
“What this paper argues is that it’s not necessarily true that the human MSCs are bad 
or that the human disease is different — although we don’t know that,” Miller says. The 
outcome was determined by what happened to the bone marrow before cells were 
isolated. In the trial, patients came in, had bone marrow taken from their hips, the MSCs 
were isolated, and they were expanded in a dish and then reinfused into the vascula-
ture. “All the clinical trials had used that paradigm because the FDA feels quite strongly 
about the possibility of rejection,” says Miller. “The studies in mice were done using 
normal human-derived cells — not MS-derived cells.”
Thus, according to Miller, the reason the clinical trials didn’t work can be traced to 
the source of the cells. “We were starting off with defective cells, in effect, and the 
clinical trial was proof of that hypothesis,” says Miller. When diseased mice were infused 
with normal cells and cells derived from MS patients, the MS-derived cells “didn’t work 
nearly as well.” An experiment to test the influence of genetics also proved negative. 
Again, the effect of diseased and normal MSCs in genetically identical mice was com-
pared. It clearly isn’t genetics, asserts Miller, “so it says something about the disease has 
compromised the capability of those cells, and that’s why I think the clinical trials failed.”
Miller is sanguine about the trials. “This is the way translational science works. You 
make an observation in the laboratory. You put it into a clinical trial. The clinical trial tells 
you something. You go back to the laboratory based on that knowledge, and then you 
redesign the clinical trial based on that new information.” He concedes, however, that 
he was “really disappointed when the trials didn’t work because we felt sure it was going 
to work — based on the animal data.”
Still, next steps are planned based on the outcome of the failed trials. Miller suggests that 
“if Jeff Cohen had taken my cells and put them in an MS patient, I hypothesize they would 
have worked.” But allergenic transplants are frowned upon by the FDA because they carry a 
higher rate of rejection, and thus more risk for people in trials.
“Will this ever be the best way to treat MS? I don’t know,” says Miller. “But I’d rather 
have an MSC transplant, even an allergenic MSC transplant, than a whole bone marrow 
transplant, which is what some people are doing now for some MS patients.”
LOOKING FOR A TREATMENT 
FOR MULTIPLE SCLEROSIS
Robert H. Miller, PhD, led 
a clinical trial to transplant 
mesenchymal stem cells (right). 
These versatile cells are particu-
larly suited as a cellular therapy 
for autoimmune diseases, 
including multiple sclerosis.
There are currently more than 
15,000 active cell therapy clinical 
trials in the United States.
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A Virtual Reality Check
USING TECHNOLOGY FOR EDUCATION AND PREOPERATIVE PLANNING
BY CAROLINE TRENT-GURBUZ
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he black and bulky headset fits snug-
ly, though Aalap Herur-Raman, senior 
virtual reality program lead from Sur-
gical Theater, can adjust the straps 
as needed. When he taps on the key-
board in front of a pair of computer 
screens, it’s impossible not to peer 
through the binocular-like eyepiece as the im-
age — upside down, per the surgical point of 
view — zooms into a skull, revealing a maze of 
colorful vasculature and brain matter.
“There are the blood vessels,” points out 
Anthony Caputy, MD, chair of the Depart-
ment of Neurological Surgery and Hugo V. Riz-
zoli Professor of Neurological Surgery at the 
George Washington University (GW) School 
of Medicine and Health Sciences (SMHS), on 
the corresponding computer screens. Herur-
Raman adjusts the opacity of the brain matter 
— thick and gray — until it fades away. “You can 
always add some of 
the brain matter back 
in,” Caputy contin-
ues, “so you can see 
where the brain is in 
relation to the blood 
vessels. You can even 
see where the tumor 
is in relation to the 
blood vessels.”
T
The tumor, a bright green mass appearing 
behind the left eye socket, is the target of the 
unique device, which provides medical pro-
fessionals and patients a 3-D glimpse of a spe-
cific condition. 
Precision Virtual Reality (VR), a product 
of Ohio-based company Surgical Theater, is 
based on an F-16 flight simulation program. A 
chance meeting at a coffee shop with a neu-
rosurgeon led the company’s founders — both 
Israeli Air Force officers — to tweak their simu-
lator program for neurological surgery.
“[It’s] actually not terribly complex,” ex-
plains Todd Goldberg, vice president of sales 
at Surgical Theater. “We are essentially a VR 
studio; instead of making music or movies, like 
you think of studios in entertainment, we make 
personalized medical content that’s useful for 
patients and surgeons. The components con-
sist of a very high-powered computer, with the 
latest, greatest, and most advanced graphics 
processing unit, or GPU, and the latest and 
greatest Intel chip. But the real brain of the 
system is the software itself.”
That software, which identifies potential 
surgical paths for brain and spinal conditions, 
is key for the SMHS Department of Neurologi-
cal Surgery’s approach to patient outcomes. 
“It’s a huge part of this three-pronged process: 
education, patient engagement, and surgical 
planning,” says Jonathan Sherman, MD, associ-
ate professor of neurological surgery at SMHS, 
who, as a longtime proponent of the tool, led 
the campaign to bring it to GW Hospital.
Right now, budding neurological surgeons 
have access to the Ammerman Lab, a micro-
surgical lab in SMHS’ Ross Hall that focuses on 
skull base, minimally invasive, microvascular, 
and spine surgeries, as well as basic science 
research. There, residents can literally get a 
“feel” for surgery — the texture of tissues, vi-
brations, additional movements — but with 
Precision VR, they get a more in-depth under-
standing of the structural aspects of the brain 
and spine.
VIRTUAL REALITY 
Through Precision Virtual 
Reality, a product based on 
an F-16 flight simulation 
program, medical profes-
sionals can see abnormali-
ties in the brain, such as 
the tumor appearing 
behind the left eye socket 
in the patient scan above.
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“[When it comes to] the education of resi-
dents and students, even professionals, Preci-
sion VR will help them better understand what 
we’ll encounter in surgery and the risks of the 
surgery,” Caputy says. “You can show [them], 
here’s the anatomy, here’s the motor pathways, 
here’s the sensory pathways, here’s the optic 
pathways. You can cut everything out around 
the pathway you want to show, whereas be-
fore, you would show it with brain slices. Their 
mind would have to put the 3-D together.”
Those complementary aspects, he adds, 
are critical to education. “We need both of 
those labs to train people.”
From a patient perspective, the tool is equal-
ly powerful for edification and engagement.
“Looking at an MRI or a CAT scan, patients 
almost tune you out because they don’t quite 
understand everything that’s going on, and 
they think they have to be a physician or health 
care professional to interpret a CAT scan or 
MRI,” says Michael Rosner, MD, vice chair of the 
Department of Neurosurgery and professor of 
neurological surgery at SMHS. “To be able to 
take all that data and just put it in the three-
dimensional model is … very, very helpful.”
GW Hospital patient Roodelyne Jean-Bap-
tiste, for example, previously had two surger-
ies to treat brain tumors, which were “brutal,” 
she says. Last winter, she was told she needed 
a third surgery, but she balked, thinking her 
tumor was relatively small. Her physician (Sher-
man) insisted, however: “He said, ‘No, we can’t 
hold off because of the size.’ We had to move 
so fast because it was already affecting me. The 
tumor was making me unable to eat and dizzy.” 
After her surgery, Sherman used Jean-
Baptiste’s MRIs and Precision VR to explain 
the complexity of her tumor. “He actually 
showed me exactly what he was talking about 
when he had to avoid a cut and what he had to 
stay away from when he went into the brain,” 
she recalls. “If I had 
had [the 3-D image] 
from the first time 
I encountered the 
procedure, I would 
have never hesitated 
to do it. You can ac-
tually see what the 
doctor is saying instead of agreeing with them 
just to agree with them.”
AT A GLANCE
Anthony Caputy, MD, 
discusses the results 
of the Precision 
Virtual Reality with 
patient Danielle 
Collins. At the age 
of 27, Collins was 
diagnosed with a 
ruptured arteriove-
nous malformation, 
an abnormal con-
nection between the 
arteries and veins.
From a patient perspective, Precision Virtual Reality 
is a powerful tool for edification and engagement.
IN THEATER
Michael Rosner, MD, 
addresses an audience at 
the George Washington Uni-
versity School of Medicine 
and Health Sciences on the 
topic of Surgical Theater.
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While Jean-Baptiste was able to get a bet-
ter handle on her specific tumor, Sherman 
and his fellow neurological surgeons gained 
insight into what surgical strategies worked 
best. With a tumor, for example, Precision VR 
includes arrows for possible surgical entries, 
and surgeons get a clear view of what obsta-
cles they may need to navigate around to en-
sure a successful procedure.
“Now, we can plan out ahead of time and re-
ally see the anatomy,” Sherman says. “It helps 
us get a better perspective on what we’re go-
ing to do surgically. We can use this technol-
ogy to plan surgical [techniques], and then in 
the OR, we can actually use it to navigate to 
what we’re doing.”
Caputy agrees, adding that by visualizing 
the environment, surgical teams can identify 
areas of concern ahead of time. “Surgeons 
can devise a strategy that best allows them 
to achieve their goal: tumor removal and the 
preservation of functions,” he says. “You want 
the most effective approach, and Precision VR 
can help you plan for that.”
GW Hospital was the first hospital in the 
mid-Atlantic region to offer the tool, a boon 
for local patients and surgeons. “This is yet 
another way that we are moving the care stan-
dard higher at GW Hospital,” says Kimberly 
Russo, MBA, MS, CEO and managing director 
of GW Hospital.
Although the tool is primarily geared to-
ward neurology-related conditions and proce-
dures at GW Hospital, its potential extends far 
beyond its technological appeal. As Goldberg 
explains, health care has a tendency to create 
silos; Precision VR, however, promises to break 
down those divisions and allow for better col-
laboration. 
“This is one of those rare technologies 
that has come along that builds bridges 
among different members of the health 
care team, among different departments of 
the hospital, and certainly among patients 
and their families,” 
Goldberg says.
Sherman likewise 
believes that the 
tool’s value isn’t lim-
ited to neurological 
surgery. “Ultimately, 
we’re [trying] to get 
this across disci-
plines,” he explains. 
“My goal is that this 
isn’t just a neurosur-
gical tool; this is … 
something we can 
use for all areas of subspecialty in surgery. 
We’re just touching the tip of the iceberg of 
what our potential is with this technology.”
A PEEK INTO THE BRAIN
Patient Danielle Collins 
peeks into her brain through 
the Precision Virtual Reality 
headset. Collins said the de-
vice provided a tangible way 
to understand the surgical 
plan, and made her feel like 
she was a part of the process. 
She said being able to see 
something that is undetect-
able by sight took away part 
of the fear of the unknown.
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Taking Away the 
Fear of the Unknown
n a Monday in early 
June 2017, Danielle 
Collins went to Pi-
lates like any other 
day. But during the 
class, she felt a sharp 
pain in her head, forcing her to leave 
early. She chalked it up to a bad mi-
graine, but after two days of suffering 
through the pain, Collins decided to 
see a doctor, only to discover she was 
experiencing life-threatening bleeding 
in her brain.
Collins, who works as a realtor at 
Chevy Chase, Maryland-based Wydler 
Brothers Real Estate, found out at 27 
years old that her brain was bleeding 
due to a ruptured arteriovenous mal-
formation (AVM), an abnormal connec-
tion between the arteries and veins.
“I was running 8 miles five times a 
week before this happened,” Collins 
says, adding that she has always been 
health conscious. “I hadn’t taken Advil, 
hadn’t had a drink of alcohol, hadn’t 
had anything in almost seven years. So 
I didn’t take Aleve or Excedrin … which 
would have thinned my blood and 
probably killed me.”
Collins soon found herself at the 
George Washington University (GW) 
Hospital looking at images of the inside 
of her brain. The device used, Precision 
Virtual Reality (VR), offers 3-D views of 
medical conditions and helps identify 
possible surgical paths.
“It provided a tangible way to under-
stand the surgical plan, and made me 
feel like I was truly a part of the process,” 
she says. “When you have an injury on 
your body, like a gash on your arm, you 
can see that. But when something is un-
detectable by sight, to provide sight to 
the areas that would be blind to you is 
incredible. It took away part of the fear 
of the unknown.”
Over the next 10 days at GW Hospi-
tal, Collins received two angiograms, an 
MRI, CAT scans, and a craniotomy. She 
expressed sincere thanks for everyone 
who helped her during her time at GW, 
including Anthony Caputy, MD, chair 
of the Department of Neurological 
Surgery, and Wayne Olan, MD, direc-
tor of interventional and endovascular 
neurosurgery at GW’s Comprehensive 
Stroke Center.“This was the best thing 
that ever happened to me,” she says. 
“No day is a bad day to me anymore; I 
woke up this morning.”
Only months removed from her sur-
gery, Collins was back at work and back 
to her morning runs. “Running is time to 
clear my head,” she says. “I run because 
I want to live a long life, I want to have a 
healthy body.”
Collins adds that she found peace in 
a Bible passage from 2 Timothy 1:7 that 
says: “For God has not given us a spirit 
of fear, but peace (love), power, and a 
sound mind.” 
“On June 12, 2017, God, with the 
team of surgeons and everyone at 
GW, gave me a sound mind, and it was 
something I never even knew I needed 
because I had no prior knowledge of 
the AVM,” she says. “It’s amazing what 
minds collectively put together were 
able to do to save my mind.” 
A MIGRAINE TURNS OUT 
TO BE LIFE-THREATENING
A sharp pain in her head 
forced Danielle Collins 
to leave a Pilates class 
early. After two days of pain, 
Collins decided to seek 
medical help. The pain she 
was feeling stemmed from 
life-threatening bleeding in 
her brain due to a ruptured 
arteriovenous malformation, 
an abnormal connection be-
tween the arteries and veins.
O
VIRTUAL REALITY GIVES PATIENTS THE INFORMATION TO ACT 
BY KATHERINE DVORAK
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Children’s National Health System, said 
Jeffrey S. Akman, MD ’81, RESD ’85, vice 
president for health affairs, Walter A. 
Bloedorn Professor of Administrative 
Medicine, and dean of SMHS.
At the outset of LaMantia’s distin-
guished career, he explored the or-
ganization and development of axon 
pathways that connect the two hemi-
spheres of the cerebral cortex and 
helped develop new methods for ob-
serving neural circuits in living animals 
over time. While an assistant professor 
of neurobiology at Duke University, he 
demonstrated that the forebrain, which 
mediates learning, memory, and cog-
nition, is built with the same molecular 
tools that build limbs, hearts, and facial 
bones. He used this work as a foun-
dation for studying the pathogenesis 
of DiGeorge, or 22q11 Deletion Syn-
drome, a genetic disorder that comes 
with the highest known genetic risk for 
autism and schizophrenia, as well as 
heart, face, and limb malformations.
LaMantia worked with the 
professorship’s namesake, Jeffrey A. 
Lieberman, MD ’75, now the Lawrence 
C. Kolb Professor of Psychiatry and 
chair of the Department of Psychiatry 
at the Columbia University College 
of Physicians and Surgeons, while the 
two were at the University of North 
Carolina (UNC) at Chapel Hill. 
“I think it represents the tying to-
gether of so many threads in my life,” 
Lieberman said, reflecting on the co-
incidence of LaMantia being picked as 
the first recipient of the professorship. 
It was “unbeknownst to Jeff [Akman] 
when he orchestrated this,” he added, 
but “Anthony was at Duke when I was at 
UNC, and I actually played a big role in 
recruiting him to UNC.”
n what he called a “milestone in 
an odyssey from the Midwest 
to the mid-Atlantic,” Anthony-
Samuel LaMantia, director of the 
George Washington University 
(GW) Institute for Neuroscience 
and professor of pharmacology and 
physiology at the GW School of Medi-
cine and Health Sciences (SMHS), be-
came the inaugural Jeffrey Lieberman 
Professor of Neurosciences during an 
installation ceremony. Surrounded by 
colleagues, family, and friends, LaMan-
tia beamed as he thanked them for the 
moment.
“If one is to achieve any measure of 
success in his or her professional and 
personal journey, that success is built 
upon the love, support, and guidance 
of family, friends, and colleagues. They 
make the journey possible,” he said.
LaMantia has played a pivotal role 
in expanding the GW neurosciences 
faculty and has been a catalyst for 
partnerships and collaborations across 
the school, the university, and with 
A Measure of Success
I
“If one is to achieve any 
measure of success in 
his or her professional 
and personal journey, 
that success is built 
upon the love, support, 
and guidance of 
family, friends, and 
colleagues. They make 
the journey possible.” 
Anthony-Samuel LaMantia, PhD
ANTHONY-SAMUEL LAMANTIA, 
director of the George Washing-
ton University (GW) Institute for 
Neuroscience and professor of 
pharmacology and physiology at 
the GW School of Medicine and 
Health Sciences, has become 
the inaugural Jeffrey Lieberman 
Professor of Neurosciences.
ANTHONY-SAMUEL LAMANTIA HONORED FOR WORK DEFINING 
THE ORIGINS OF A DEVASTATING NEURODEVELOPMENTAL DISORDER
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